Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Insmed (NASDAQ:INSM) with a Buy and announces $188 price target.
Share
Why It Matters
A big bank analyst says Insmed looks like a good company again. This means experts think the stock might do well soon.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.